Anti-Human LY6G6D/MEGT1 Reference Antibody (1G4, RUO)

Catalog No.	HF554016
Brand	abinScience
Host species	Human
Species reactivity	Human
Form	Liquid
Storage buffer	0.01M PBS pH 7.4.
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Target	MEGT1, G6D, Megakaryocyte-enhanced gene transcript 1 protein, NG25, LY6G6D, C6orf23, Protein Ly6-D, Lymphocyte antigen 6 complex locus protein G6d
References	1. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. [HF554016] 2. Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28. [HF554016] 3. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737. [HF554016]
Purification	Protein A/G purified from cell culture supernatant.
Biological activity	NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC 50 s of 149 nM and 21.7 nM, respectively. NG25 also potently suppresses several kinases such as LYN, CSK, FER, p38α, ABL,ARG and SRC, with IC 50 s of 12.9, 56.4, 82.3, 102, 75.2, and 113 nM, respectively [1]. NG25 is very potent suppressor of CpG B- or CpG A-stimulated secretion of IFNα and CL097-stimulated secretion of IFNβ, with complete inhibition by 400 nM [2]. NG25 treatment reduces cell viability of all tested breast cancer cell lines in a dose dependent manner. NG25 (2?uM) enhances the cytotoxic effect of Dox on breast cancer cells [3].
Endotoxin level	< 10 EU/mg as determined by LAL method.
Expression system	Mammalian cells
Accession	O95868
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Clone ID	1G4
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)